Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-01-18

FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

View source ↗

Summary

The FDA approved a supplemental application for EGRIFTA WR (tesamorelin) from Theratechnologies Inc., indicating an update or addition to its labeling stemming …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EGRIFTA WR (TESAMORELIN)

Snippet

SUPPL AP for EGRIFTA WR (TESAMORELIN)